Company Overview
Viemed Healthcare, Inc. operates as a provider of home medical equipment and post-acute respiratory healthcare services within the United States, focusing specifically on respiratory disease management solutions such as the treatment of chronic obstructive pulmonary disease. The company functions within the Healthcare sector and the Medical Devices industry, positions that signify its alignment with essential patient care needs and the broader demand for durable medical equipment and specialized therapy services. This entity employs 1382 individuals and maintains a market capitalization of $350.51M, reflecting its status as a mid-cap company with a tangible operational footprint. The annual revenue of $270.28M indicates a substantial scale of operations relative to its peers, suggesting that Viemed has established a significant presence in the competitive landscape of home healthcare while managing a workforce of nearly 1,400 employees to deliver its specific medical solutions.
Financial Health
The company reported a trailing twelve-month revenue of $270.28M with a corresponding net income of $14.93M, while EBITDA stands at $50.45M, revealing a substantial gap between pre-tax operating earnings and bottom-line profit that highlights the impact of interest, taxes, depreciation, and amortization on the final financial result. Free cash flow is reported at $15.72M, which demonstrates that the business generates sufficient liquidity after capital expenditures to support ongoing operations, fund potential acquisitions, or provide a buffer against economic downturns without relying on external financing. Analysis of the margin structure shows a gross margin of 57.5%, indicating high efficiency in production and pricing power for medical equipment and services, whereas an operating margin of 11.5% and a profit margin of 5.5% suggest that significant operational expenses are required to maintain the healthcare delivery model. The balance sheet shows $13.50M in cash against $15.95M in debt, resulting in a debt-to-equity ratio of 11.11, which characterizes the company as moderately leveraged given the relatively small cash reserve compared to its debt obligations. A current ratio of 1.18 indicates that the company holds slightly more current assets than current liabilities, suggesting a tight but manageable short-term liquidity position that may require careful cash flow management. Return on Equity is 11.1% and Return on Assets is 7.3%, metrics that collectively reveal that management is effectively utilizing shareholder equity and the total asset base to generate profits, though the ROA being lower than ROE is consistent with the presence of debt on the balance sheet.
Valuation Assessment
The stock carries a trailing P/E ratio of 24.54 and a forward P/E of 22.70, implying that the market expects earnings growth that would justify a lower multiple in the future, or conversely, that current earnings are being discounted relative to future projections. The price-to-book ratio is 2.44, which indicates that the market values the company at more than double its net asset book value, suggesting a premium assigned to its intangible assets, brand, and growth potential in the respiratory care sector. Alternative valuation metrics such as a price-to-sales ratio of 1.30 and an EV/EBITDA of 6.75 provide context for revenue-rich but potentially capital-intensive business models, showing that the company trades at a reasonable multiple of its sales and earnings power. The 52-week high is $10.06 and the 52-week low is $5.93, meaning the current trading price sits within this historical range, though the specific percentage distance from these extremes depends on the real-time market price not provided in the static data. With a beta of 1.23, the stock exhibits price volatility that is higher than the broader market average, indicating that it will likely experience amplified price swings during periods of overall market movement.
Growth & Income
Revenue growth over the past year is 25.5% and earnings growth is 29.8%, indicating that profitability is expanding at a faster rate than top-line sales, which often signals improving operational leverage or pricing power in the marketplace. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings are retained within the business to fuel internal growth, reinvestment in equipment, or debt reduction rather than being distributed to shareholders. This reinvestment strategy aligns with the capital-intensive nature of the medical device and home healthcare sectors, where continuous investment in R&D and service expansion is necessary to maintain market share. Overall, the growth and income profile is defined by strong double-digit revenue and earnings expansion without the yield component, prioritizing capital appreciation and business scaling over immediate income distribution.